Paratek Pharmaceuticals, Inc.

PRTKNASDAQHealthcare

$2.23

+$0.04(+1.83%)

Market Cap$127828952

P/E Ratio—

52W High$3.65

52W Low$1.29

Avg Volume631K

Open$2.19

Beta1.70

Overview

Paratek Pharmaceuticals, Inc. (PRTK) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

PRTK · free cash flow · updated Jun 9, 2026

Core FCF metrics

PRTK · FCF · TTM · margin & CAGR

Free cash flow was −$66.2M for FY2022 (fiscal year ending 2022-12-31), down 36.0% year-over-year The FCF margin was -43.9%.

FY2022 Free Cash Flow−$66.2M▼ -36.0% YoY

Trailing 12M (TTM)−$23.3Mtrailing 4 quarters sum

FCF Margin-43.9%−$66.2M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

PRTK · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2022Latest−$66.1M(0M)−$66.2M▼ 36.0%-43.9%

FY2021−$48.3M(0M)−$48.6M▲ +53.1%-40.2%

FY2020−$103.4M(0M)−$103.8M▲ +22.7%-238.5%

FY2019−$134.0M(0M)−$134.3M▼ 65.3%-811.7%

FY2018−$81.2M(0M)−$81.2M▼ 1.9%-474.6%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

PRTK · P/FCF · FCF yield · FCF per share

Paratek Pharmaceuticals, Inc. (PRTK) reported negative free cash flow of −$0.07B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2022 · 2022-12-31

Cash flow statement summary

PRTK · cash flow statement · operating / investing / financing

For FY2022, Paratek Pharmaceuticals, Inc. generated −$66.1M in operating cash flow and spent 0M in capital expenditures, yielding −$66.2M in free cash flow.

Operating Activities

−$66.1M

Cash from core business operations

2022-12-31

Investing Activities

+$14.8M

CapEx, acquisitions & investments

2022-12-31

Financing Activities

+$5.1M

Buybacks, dividends & debt

2022-12-31

FCF FormulaOperating CF (−$66.1M) − |CapEx| (0M) = FCF (−$66.2M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

PRTK vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Paratek Pharmaceuticals, Inc.YOU

PRTK

−$66.2M-36.0%-43.9%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Paratek Pharmaceuticals, Inc. (PRTK) reported free cash flow of −$66.2M for FY2022 (fiscal year ending 2022-12-31), down 36.0% year-over-year. The FCF margin was -43.9%.

Based on available data, Paratek Pharmaceuticals, Inc. has maintained positive free cash flow for at least 1 fiscal year(s). FCF peaked at $512,000 in FY2009.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

PRTK free cash flow · 8 questions

Paratek Pharmaceuticals, Inc. free cash flow was −$66.2M for FY2022, down 36.0% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$23.3M.

PRTK free cash flowPRTK FCFPRTK FCF 2022PRTK free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Paratek Pharmaceuticals, Inc. · Paratek Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026